CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 1.80 +0.03 (1.69%)
price chart
CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results
All that remains to be done in this pivotal Phase 3 study is to continue to track patient survival until the primary endpoint has been met.
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
CEL-SCI Announces Robert Watson Joins Its Board of Directors
“I am excited to join CEL-SCI's board at this time, as the Company approaches evaluating the endpoint of its Phase 3 results, which may lead to a new and much needed immunotherapy to treat head and neck cancer.
CEL-SCI Corp. CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.
CEL-SCI Corp (CVM) Announces US Patent Office Allows New Patent For LEAPS ...
CEL-SCI Corporation (NYSE American: CVM) today announced the U.S. Patent and Trademark Office has allowed a patent titled, “Method for Inducing an Immune Response and Formulations Thereof” for the Company's LEAPS technology.
At First Glance, Such A Possibility Seems Ridiculous: CEL-SCI Corporation ...  Post Analyst
CEL-SCI Corporation Releases Letter to Shareholders
We are giving you an update on clinical hold communications with the U.S. Food and Drug Administration (FDA), the “Agency”, regarding the previously announced partial clinical hold of CEL-SCI's Phase 3 clinical trial of its investigational drug ...
CEL-SCI Corporation (CVM) Stock: Takes A Dive On FDA Clinical Hold  CNA Finance (press release)
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
CEL-SCI Announces Adjustment to Warrant Exercise Price
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 ...